Zimbabwe has declined a significant US healthcare agreement valued at 367 million US dollars (£272m) spanning five years because of Washington's request for confidential biological samples.
This rejection was revealed after a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson has since clarified that the US was requesting health data for scientific study and profit while was unwilling to guarantee the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further talks to secure a agreement acceptable to both sides so the nation's critical HIV programme can proceed.
Broader Context
Zimbabwe's decision follows a comparable case in Kenya, where a high court halted a similar health funding agreement after legal challenges were filed about the safety of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump claimed its spending was "inefficient" and his administration was seeking government-to-government deals to boost openness and accountability.
According to reports, 16 African countries have so far agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to share its genetic material and health information indefinitely, with no corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"In essence, our country would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our population if a new pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral health agreements were upending frameworks already established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future pandemics.
"This mechanism is designed to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We welcome continued dialogue with our US partners on how subsequent co-operation might be arranged in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body stated it acknowledged the official position, but suggested that talks need to persist given that much of the nation's Aids initiatives relied on external financing.
"In cases where technical issues exist, including those relating to data governance or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
This impasse highlights the complex challenges between receiving much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.